1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

Partnerships, Licensing, Investments and MandA Deals and Trends in Pharmaceuticals - Q1 2016
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals and Healthcare, Global, Deal Summary, Q1 2016 15
2.1 Pharmaceuticals and Healthcare, Global, Deals Analysis, Q1 2016 15
2.2 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals, Q1 2016 17
2.3 Pharmaceuticals and Healthcare, Global, by Type, Deal Values, Q1 2016 18
2.4 Pharmaceuticals and Healthcare, Global, Top Deals, Q1 2016 19
2.4.1 Shire to Acquire Baxalta for USD32 Billion 19
2.4.2 Mylan to Acquire Meda for USD9.9 Billion 21
2.4.3 Abbott Labs to Acquire Alere 23
2.4.4 Sanofi Prices Public Offering of Notes for USD2 Billion 24
2.4.5 Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 24
3 Pharmaceuticals and Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals and Healthcare, Global, MandA, Q1 2016 26
3.1.1 Top MandA Deals in Q1 2016 27
3.1.2 Pharmaceuticals and Healthcare, Global, MandA Deals, by Therapy Area, Q1 2015 - Q1 2016 28
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Q1 2016 29
3.2.1 Top Initial Public Offerings in Q1 2016 30
3.2.2 Top Secondary Offerings in Q1 2016 31
3.2.3 Top PIPE Deals in Q1 2016 31
3.2.4 Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q1 2015-Q1 2016 32
3.2.5 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2015 - Q1 2016 32
3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, Q1 2016 34
3.3.1 Top Venture Financing Deals in Q1 2016 35
3.3.2 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2016 36
3.3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2016 37
3.3.4 Pharmaceuticals and Healthcare, Global, Venture Capital, by Therapy Area, Q1 2015 - Q1 2016 38
3.3.5 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Q1 2015 - Q1 2016 39
3.3.6 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q1 2015 - Q1 2016 40
3.4 Pharmaceuticals and Healthcare, Global, Private Equity Deals, Q1 2016 41
3.4.1 Top Private Equity Deals in Q1 2016 42
3.4.2 Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2015 - Q1 2016 43
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q1 2016 44
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q1 2016 44
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2015 - Q1 2016 46
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q1 2016 47
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2016 48
4.3.2 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2016 48
4.3.3 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2016 49
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 50
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2015 - Q1 2016 52
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2015 - Q1 2016 53
4.7 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 55
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, Q1 2016 57
5.1 Pharmaceutical and Healthcare, Global, Licensing Agreements, Q1 2016 57
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 59
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2016 60
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2016 61
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2016 61
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2015 - Q1 2016 62
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 - Q1 2016 63
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 - Q1 2016 65
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 - Q1 2016 66
5.7 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 - Q1 2016 68
6 Pharmaceuticals and Healthcare, Global, MandA Financial Analysis 70
6.1 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2015 - Q1 2016 70
6.2 Pharmaceuticalsand Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2015 - Q1 2016 72
6.3 Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
6.4 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 - Q1 2016 74
6.5 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2015 - Q1 2016 75
6.6 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
7 Pharmaceuticals and Healthcare, Global, Deal Summary by Therapy Area 77
7.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, Q1 2016 77
7.1.1 Oncology - Deals of the Quarter 79
7.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, Q1 2016 81
7.2.1 Central Nervous System - Deals of the Quarter 82
7.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, Q1 2016 84
7.3.1 Infectious Disease - Deals of the Quarter 85
7.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, Q1 2016 88
7.4.1 Immunology - Deals of the Quarter 89
7.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, Q1 2016 91
7.5.1 Metabolic Disorders - Deals of the Quarter 92
7.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, Q1 2016 94
7.6.1 Cardiovascular - Deals of the Quarter 96
7.7 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, Q1 2016 98
7.7.1 Gastrointestinal - Deals of the Quarter 99
7.8 Pharmaceuticals and Healthcare, Global, Hematological Disorders Deals, Q1 2016 101
7.8.1 Hematological Disorders - Deals of the Quarter 102
7.9 Pharmaceuticals and Healthcare, Global, Respiratory Deals, Q1 2016 104
7.9.1 Respiratory - Deals of the Quarter 105
7.10 Pharmaceuticals and Healthcare, Global, Dermatology Deals, Q1 2016 107
7.10.1 Dermatology - Deals of the Quarter 108
8 Deal Summary by Geography 110
8.1 Pharmaceuticals and Healthcare, North America Region, Deals, Q1 2016 110
8.1.1 North America - Deals of the Quarter 112
8.2 Pharmaceuticals and Healthcare, Europe Region, Deals, Q1 2016 113
8.2.1 Europe - Deals of the Quarter 114
8.3 Pharmaceuticals and Healthcare, Asia-Pacific, Deals, Q1 2016 118
8.3.1 Asia-Pacific - Deals of the Quarter 119
8.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, Q1 2016 121
8.4.1 Rest of the World - Deals of the Quarter 122
9 Pharmaceuticals and Healthcare, Global, Top Advisors 124
9.1 Pharmaceuticals and Healthcare, Global Top Financial Advisors, MandA, Q1 2015 - Q1 2016 124
9.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2015 - Q1 2016 126
10 Appendix 127
11 Further Information 129
11.1 Methodology 129
11.2 About GlobalData 130
11.3 Disclosure information 131
11.4 Disclaimer 131

1.1 List of Tables
Table 1: Pharmaceuticals and Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 16
Table 2: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2016 18
Table 3: Pharmaceuticals and Healthcare, Global, Top Deals, Q1 2016 19
Table 4: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 27
Table 5: Pharmaceuticals and Healthcare, Global, Top MandA Deals, Q1 2016 27
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2015 - Q1 2016 28
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 30
Table 8: Pharmaceuticals and Healthcare, Global, Top Initial Public Offering Deals, Q1 2016 30
Table 9: Pharmaceuticals and Healthcare, Global, Top Secondary Offering Deals, Q1 2016 31
Table 10: Pharmaceuticals and Healthcare, Global, Top PIPE Deals, Q1 2016 31
Table 11: Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q1 2015-Q1 2016 32
Table 12: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 33
Table 13: Pharmaceuticals and Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 35
Table 14: Pharmaceuticals and Healthcare, Global, Top Venture Capital Deals, Q1 2016 35
Table 15: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2016 37
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 38
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 39
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q1 2015 - Q1 2016 40
Table 19: Pharmaceuticals and Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 42
Table 20: Pharmaceuticals and Healthcare, Global, Top Private Equity Deals, Q1 2016 42
Table 21: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 43
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 45
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 46
Table 24: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 47
Table 25: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), Q1 2016 48
Table 26: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2016 48
Table 27: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2016 49
Table 28: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 51
Table 29: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 54
Table 30: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 56
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 58
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 60
Table 33: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2016 60
Table 34: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2016 61
Table 35: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2016 61
Table 36: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 62
Table 37: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment (US$ m), Q1 2015 - Q1 2016 64
Table 38: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 67
Table 39: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 69
Table 40: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 - Q1 2016 71
Table 41: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 - Q1 2016 72
Table 42: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
Table 43: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2015 - Q1 2016 74
Table 44: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 - Q1 2016 75
Table 45: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
Table 46: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 78
Table 47: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 82
Table 48: Pharmaceuticals and Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 85
Table 49: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 89
Table 50: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 92
Table 51: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 95
Table 52: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 99
Table 53: Pharmaceuticals and Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 102
Table 54: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 105
Table 55: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 108
Table 56: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 111
Table 57: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 114
Table 58: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 119
Table 59: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 122
Table 60: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 125
Table 61: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 126
Table 62: Pharmaceuticals and Healthcare, Deals' Key Financials, Global Acquisition Deals, Q1 2015-Q1 2016 127

1.2 List of Figures
Figure 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 15
Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%), Q1 2016 17
Figure 3: Pharmaceuticals and Healthcare, Global, Deal Values (%), Q1 2016 18
Figure 4: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$m), Q1 2015 - Q1 2016 26
Figure 5: Pharmaceuticals and Healthcare, Global, MandAs, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2015 - Q1 2016 28
Figure 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 29
Figure 7: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2015 - Q1 2016 32
Figure 8: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 34
Figure 9: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2016 36
Figure 10: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2016 37
Figure 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 - Q1 2016 38
Figure 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 39
Figure 13: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 41
Figure 14: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 - Q1 2016 43
Figure 15: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 44
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 46
Figure 17: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 47
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 50
Figure 19: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 52
Figure 20: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q1 2015 - Q1 2016 53
Figure 21: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2015 - Q1 2016 55
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 57
Figure 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 59
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 62
Figure 25: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 63
Figure 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2015 - Q1 2016 65
Figure 27: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2015 - Q1 2016 66
Figure 28: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q1 2015 - Q1 2016 68
Figure 29: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 - Q1 2016 70
Figure 30: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 - Q1 2016 72
Figure 31: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 - Q1 2016 73
Figure 32: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 - Q1 2016 74
Figure 33: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 - Q1 2016 75
Figure 34: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 - Q1 2016 76
Figure 35: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 77
Figure 36: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 81
Figure 37: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 84
Figure 38: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 88
Figure 39: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 91
Figure 40: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 94
Figure 41: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 98
Figure 42: Pharmaceuticals and Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 101
Figure 43: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 104
Figure 44: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 107
Figure 45: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 110
Figure 46: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 113
Figure 47: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 118
Figure 48: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 121
Figure 49: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 124
Figure 50: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 - Q1 2016 126

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.